The Oral Cancer Treatment Market Outlook And Analysis By Type (Squamous
Cell Carcinoma, Minor Salivary Gland Carcinomas), Treatment (Surgery,
Radiotherapy, Chemotherapy), End Users (Research Organization, Academic
Institutes) - Forecast till 2030
The treatment for oral cancer is a prime
area of research as it is generally discovered late in its development.
Industry leaders are emphasizing the development of more effective diagnosis.
Market Research Future (MRFR) has found out in its latest study that the global
oral cancer treatment market is anticipated to exhibit a CAGR of 5.40% during
the forecast period 2022 to 2030. The need for early detection of oral cancer
is expected to boost the revenue growth of the market in the years to come.
The increasing burden of the disease is
poised to catapult the oral cancer treatment market on an upward trajectory in
the nearby future. As per the statistics presented by the Oral Cancer
Foundation, 53,000 Americans are estimated to be diagnosed with oral or
oropharyngeal cancer in 2019. Habits such as tobacco addiction trigger the
rising risk of developing oral cancer. Increasing cases of smoking addiction
are anticipated to propel the expansion of the oral cancer market in the
forthcoming years.
The rising healthcare expenditure is likely
to influence the growth pattern of the market positively over the next couple
of years. On the contrary, the risk of recurrence of the disease, coupled with
the adverse effects associated with the treatment, remains an impediment to
market growth. In addition, the high cost of the treatment is expected to check
the proliferation of the oral cancer treatment market across the review period.
Market Segmentation:
The global oral cancer treatment market, by
type, has been segmented into verrucous carcinoma, squamous cell carcinoma,
lymphomas, minor salivary gland carcinomas, and others.
On the basis of treatment, the oral cancer
treatment market has been segmented into surgery, chemotherapy, radiotherapy,
photodynamic therapy (PDT), and others. The surgery segment is further
sub-segmented into glossectomy, tumor resection, Mohs micrographic surgery,
laryngectomy, and others. The chemotherapy segment has been sub-segmented into
carboplatin, cisplatin, 5-fluorouracil (5-FU), and others.
Based on end-users, the global oral cancer treatment market share has been segmented into
hospitals & clinics, academic institutes, research organizations, and
others.
Regional Analysis:
By region, the global oral cancer treatment
market has been segmented into Americas, Europe, Asia Pacific, and the Middle
East & Africa (MEA). Americas is projected to lead the global market owing
to the exponentially rising patient population. The region is also witnessing a
drastic rise in cancer expenditure which is forecasted to favor the expansion
of the oral cancer treatment market in the region. Europe is the second-largest
market for oral cancer. Rising investments in research & development are
anticipated to fuel the growth of the oral cancer treatment market in the region.
Asia Pacific has been projected to expand at the highest CAGR over the
assessment period. The Middle East & Africa is poised to retain the least
share of the market in the forthcoming years.
Competitive Tracking:
The key players participating in the global
oral cancer treatment market are Qilu Pharmaceutical Co., Ltd. (Asia Pacific),
Bristol-Myers Squibb Company (U.S.) Teva Pharmaceutical Industries Ltd.
(Israel), F. Hoffmann-La Roche Ltd (Europe), Eli Lilly and Company. (U.S.),
Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), and Novartis AG (Europe).
Industry News:
In May 2019, Bristol-Myers Squibb Company,
an American pharmaceutical company, participated in the UBS Global Healthcare
Conference.
In January 2019, an American pharmaceutical
company, Bristol-Myers Squibb Company, announced its plan of acquiring Celgene
Corporation, an American biotechnology company, for creating a premier
innovative biopharma company.
In September 2018, Qilu Pharmaceutical, a
leading pharmaceutical company in China, announced the receipt of FDA approval
for Palonosetron HCl Injection (2.5mg/5ml), a generic Aloxi® Injection, which
is used in the treatment and prevention of chemotherapy-induced vomiting and
nausea.
About Market
Research Future:
At Market
Research Future (MRFR), we enable our customers to unravel the complexity of
various industries through our Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), & Consulting Services. MRFR team have supreme
objective to provide the optimum quality market research and intelligence
services to our clients.
Contact us:
Market Research
Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,
5Th Floor,
New York, New
York 10013
United States of
America
+1 628 258 0071
Email:
sales@marketresearchfuture.com
Comments
Post a Comment